Stuart Rich - 08 Dec 2025 Form 4 Insider Report for TENAX THERAPEUTICS, INC. (TENX)

Role
Chief Medical Officer, Director
Signature
/s/ S. Halle Vakani, as Attorney-in-Fact
Issuer symbol
TENX
Transactions as of
08 Dec 2025
Transactions value $
$50,793
Form type
4
Filing time
10 Dec 2025, 18:48:57 UTC
Previous filing
05 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Rich Stuart Chief Medical Officer, Director 101 GLEN LENNOX DRIVE, SUITE 300, CHAPEL HILL /s/ S. Halle Vakani, as Attorney-in-Fact 10 Dec 2025 0001841785

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TENX Common Stock Purchase $25.3K +2.5K +100% $10.10 5K 08 Dec 2025 By Stuart Rich Revocable Trust DTD 11/18/1996 F1, F2
transaction TENX Common Stock Purchase $25.5K +2.5K +90.38% $10.22 5.27K 09 Dec 2025 Direct F3
holding TENX Common Stock 1.19K 08 Dec 2025 By Stuart Rich 2022 Irrevocable Trust F4
holding TENX Common Stock 1.19K 08 Dec 2025 By Andrea Rich 2021 Irrevocable Trust F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TENX Stock Option (right to buy) 157 08 Dec 2025 Common Stock 157 $2,848.00 Direct F6
holding TENX Stock Option (right to buy) 63 08 Dec 2025 Common Stock 63 $992.00 Direct F7
holding TENX Stock Option (right to buy) 119 08 Dec 2025 Common Stock 119 $3.55 Direct F8
holding TENX Stock Option (right to buy) 500K 08 Dec 2025 Common Stock 500K $5.94 Direct
holding TENX Stock Option (right to buy) 625K 08 Dec 2025 Common Stock 625K $5.89 Direct F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $9.76 to $10.42. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F2 The Reporting Person is trustee of the Stuart Rich Revocable Trust DTD 11/18/1996 and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F3 This transaction was executed in multiple trades at prices ranging from $9.70 to $10.45. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F4 The Reporting Person is special asset advisor to the Stuart Rich 2022 Irrevocable Trust, a Spousal Lifetime Access Trust (the "Trust"). As such, the Reporting Person has voting and dispositive power over the reported securities held in the Trust, however disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F5 The Reporting Person is co-trustee of the Andrea Rich 2021 Irrevocable Trust and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F6 The options vest and become exercisable in four equal installments, with 25% vesting after the start of a Phase 3 clinical trial, 25% vesting after the database lock with respect to the trial, 25% vesting after the opening of an Investigational New Drug Application with the U.S. Food and Drug Administration ("FDA"), and 25% vesting after the approval from the FDA, subject to the Reporting Person's continued employment.
F7 The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment.
F8 The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment.
F9 The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.